Meta Biomed Co. Ltd (059210) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.05 Billion ≈ $714.42K USD) by net assets (₩121.24 Billion ≈ $82.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Meta Biomed Co. Ltd (059210) total market value for the company's overall valuation and market capitalisation.
Meta Biomed Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Meta Biomed Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Meta Biomed Co. Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Meta Biomed Co. Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinar Su Sanayi ve Ticaret AS
IS:PINSU
|
0.111x |
|
Infas Holding AG
F:IFS
|
-2.339x |
|
ZEN Graphene Solutions Ltd
NASDAQ:ZTEK
|
-0.103x |
|
Jinhui Shipping and Transportation Limited
F:J4O
|
0.038x |
|
Cimbeton Hazirbeton ve Prefabrik Yapi Elemanlari Sanayi ve Ticaret AS
IS:CMBTN
|
0.316x |
|
James Bay Minerals Ltd
AU:JBY
|
N/A |
|
Pratama Widya Tbk Pt
JK:PTPW
|
0.027x |
|
MGB Bhd
KLSE:7595
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Meta Biomed Co. Ltd from 2011 to 2024. View Meta Biomed Co. Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩93.34 Billion ≈ $63.25 Million |
₩22.63 Billion ≈ $15.34 Million |
0.242x | +72.44% |
| 2023-12-31 | ₩72.66 Billion ≈ $49.24 Million |
₩10.22 Billion ≈ $6.92 Million |
0.141x | -6.98% |
| 2022-12-31 | ₩60.59 Billion ≈ $41.06 Million |
₩9.16 Billion ≈ $6.21 Million |
0.151x | -20.83% |
| 2021-12-31 | ₩58.32 Billion ≈ $39.52 Million |
₩11.14 Billion ≈ $7.55 Million |
0.191x | +88.43% |
| 2020-12-31 | ₩47.98 Billion ≈ $32.51 Million |
₩4.86 Billion ≈ $3.29 Million |
0.101x | +88.40% |
| 2019-12-31 | ₩53.27 Billion ≈ $36.10 Million |
₩2.86 Billion ≈ $1.94 Million |
0.054x | +150.87% |
| 2018-12-31 | ₩49.97 Billion ≈ $33.86 Million |
₩-5.28 Billion ≈ $-3.58 Million |
-0.106x | -1857.36% |
| 2017-12-31 | ₩46.01 Billion ≈ $31.18 Million |
₩-248.51 Million ≈ $-168.41K |
-0.005x | -105.54% |
| 2016-12-31 | ₩51.59 Billion ≈ $34.96 Million |
₩5.03 Billion ≈ $3.41 Million |
0.098x | +0.59% |
| 2015-12-31 | ₩50.87 Billion ≈ $34.47 Million |
₩4.93 Billion ≈ $3.34 Million |
0.097x | +1547.11% |
| 2014-12-31 | ₩44.20 Billion ≈ $29.96 Million |
₩-296.24 Million ≈ $-200.76K |
-0.007x | -108.04% |
| 2013-12-31 | ₩44.54 Billion ≈ $30.18 Million |
₩3.71 Billion ≈ $2.52 Million |
0.083x | -11.04% |
| 2012-12-31 | ₩40.89 Billion ≈ $27.71 Million |
₩3.83 Billion ≈ $2.60 Million |
0.094x | -10.84% |
| 2011-12-31 | ₩39.05 Billion ≈ $26.46 Million |
₩4.10 Billion ≈ $2.78 Million |
0.105x | -- |
About Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more